1. Home
  2. TNON vs PPCB Comparison

TNON vs PPCB Comparison

Compare TNON & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

BUY

Current Price

$2.27

Market Cap

2.8M

Sector

Health Care

ML Signal

BUY

Logo Propanc Biopharma Inc.

PPCB

Propanc Biopharma Inc.

BUY

Current Price

$0.28

Market Cap

2.6M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
TNON
PPCB
Founded
2012
2007
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
2.6M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
TNON
PPCB
Price
$2.27
$0.28
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $44.38
N/A
AVG Volume (30 Days)
★ 255.9K
196.5K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.90
N/A
EPS
N/A
★ N/A
Revenue
★ $3,944,000.00
N/A
Revenue This Year
$46.86
N/A
Revenue Next Year
$63.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 20.35
N/A
52 Week Low
$2.40
$0.06
52 Week High
$45.50
$6.79

Technical Indicators

Market Signals
Indicator
TNON
PPCB
Relative Strength Index (RSI) 34.65 23.83
Support Level N/A $0.24
Resistance Level $4.18 $0.40
Average True Range (ATR) 0.22 0.04
MACD -0.01 0.01
Stochastic Oscillator 1.94 0.04

Price Performance

Historical Comparison
TNON
PPCB

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: